VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.05
+7.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.93
From 52W high−59.57%
Volume1.26M
Market cap$126.32M
P/E (TTM)—
P/S (TTM)3.7x
Div yield—
Key dataOct 19, 2026
Open
$1.93
From 52W high
−59.57%
Volume
1.26M
Market cap
$126.32M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
24.9
MomentumView details →
1D Return
+7.89%
YTD Return
−49.56%
SummaryUpdated Jun 1, 2026
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a clinical-stage gene therapy company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in November 2015 and has since focused on developing innovative treatments for neurological diseases using advanced gene therapy technologies. Voyager specializes in creating adeno-associated virus (AAV) gene therapies that can cross the blood-brain barrier to deliver therapeutic payloads directly to the central nervous system, addressing some of the most challenging neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP reduced its stake in Voyager Therapeutics, Inc. by 19.3%, selling 208,931 shares during the quarter, leaving 875,568 shares, as disclosed in a 13F filing.68d agoVoyager Therapeutics reported Q2 2026 financial results with revenue of $3.2 million, a net loss of $24.5 million, and diluted EPS of -$0.40.75d ago